Antibiotic susceptibility of Vibrio cholerae 01: evolution after prolonged curative and preventive use during the 2004 cholera epidemics in Douala (Cameroon);Évolution de la sensibilité de Vibrio cholerae 01 après utilisation prolongée d'antibiotiques en traitement et en prophylaxie au cours de l'épidémie de choléra de Douala (Cameroun) 2004

Medecine et Maladies Infectieuses

Volumn 36, Issue 6, 2006, Pages 329-334

  Guevart E ^a   Solle, J ^b   Mouangue, A ^b   Noeske, J ^c   Bita, A ^b   Fonkoua, M C ^d   Ndayo Wouafo, M ^d  

^a Délégation provinciale de la santé publique du Littoral ^*  (France)

^b Delegation Provinciale de la Sante Publique du Littoral   (Cameroon)

^c Financial Systems Development Section   (Germany)

^d CENTRE PASTEUR DU CAMEROUN   (Cameroon)

Author keywords

Amoxicillin; Cholera; Doxycycline

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CHLORAMPHENICOL; COLISTIN; COTRIMOXAZOLE; CYCLINE; DOXYCYCLINE; GENTAMICIN; NALIDIXIC ACID; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFANILAMIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CAMEROON; CHEMOPROPHYLAXIS; CHOLERA; CONTROLLED STUDY; EPIDEMIC; FEMALE; FOLLOW UP; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MALE; STRAIN IDENTIFICATION; VIBRIO CHOLERAE; COMMUNICABLE DISEASE; CROSS INFECTION; DRUG EFFECT; INCIDENCE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CAMEROON; CHOLERA; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; VIBRIO CHOLERAE;

EID: 33746325138     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2005.11.020     Document Type: Article

References (34)

1. Usubutun S., Agalar C., Diri C., and Turkyilmaz R. Single dose ciprofloxacin in cholera. Eur. J. Emerg. Med. 4 3 (1997) 145-149
2. Bhattacharya S.K. An evaluation of current cholera treatment. Expert Opin. Pharmacother. 4 2 (2003) 141-146
3. Dutta D., Bhattacharya S.K., Bhattacharya M.K., Deb A., Deb M., Manna B., et al. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae 0139 infection. J. Antimicrob. Chemother. 37 3 (1996) 575-581
4. o 8.
5. e édition américaine (1992), Flammarion., Paris 632-633
6. OMS. Guide pour la lutte contre le choléra. Genève : OMS (1993)
7. Weir E., and Haider S. Cholera outbreaks continue. CMAJ 170 7 (2004) 1092-1093
8. Garrigue P., Ndayo M., Sicard J.M., Fonkoua M.C., Lemao G., Durand J.P., et al. Résistance aux antibiotiques des souches de Vibrio cholerae El Tor isolées à Douala (Cameroun). Bull. Soc. Pathol. Exot. 79 3 (1986) 305-312
9. Shears P. Recent developments in cholera. Curr. Opin. Infect. Dis. 14 5 (2001) 553-558
10. Dromigny J.A., Rakoto-Alson O., Rajaonatahina D., Migliani R., Ranjalahy J., and Mauclere P. Emergence and rapid spread of tetracycline-resistant Vibrio cholerae strains, Madagascar. Emerg. Infect. Dis. 8 3 (2002) 336-338
11. Sen Gupta R.G., Sircar B.K., Mondal S., De S.P., Sen D., Sikder S.N., et al. Effects of doxycycline on transmission of Vibrio cholerae infection among family contacts of cholera patients in Calcutta. Bull. WHO 56 2 (1978) 323-326
12. Goh K.T., Teo S.H., Lam S., and Ling M. Person-to-person transmission of cholera in a psychiatric hospital. J. Infect. 20 3 (1990) 193-200
13. Martin C, et un groupe d'experts. Recommandations pour la pratique de l'antibioprophylaxie en chirurgie. Actualisation 1999. SFAR-Anaes. Conférences de consensus. Paris 1999.
14. Alam A.N., Alam N.H., Ahmed T., and Sack D.A. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 300 6740 (1990) 1619-1621
15. Krishna B.V., Patil A., Nadgir S.D., and Chandrasekhar M.R. Incidence of Vibrio cholerae serogroup 0139 infection with low virulence in Hubli, Karnataka (India). Indian J. Pathol. Microbiol. 46 1 (2003) 142-144
16. Dhar U., Bennish M.L., Khan W.A., Seas C., Huq Khan E., Albert M.J., et al. Clinical features, antimicrobial susceptibility and toxin production in Vibrio cholerae 0139 infection: comparison with V. cholerae 01 infection. Trans. R. Soc. Trop. Med. Hyg. 90 4 (1996) 402-405
17. Farmer J.J., and Kelly M.T. Enterobacteriaceae. In: Balows A., Hausler Jr. W.J., Herman K.L., Isenberg H.D., and Shadomy H.J. (Eds). Manual of Clinical Microbiology. Fifth edition (1991), American Society for Microbiology, Washington, DC 370-373
18. Sarkar K. Role of oral rehydration therapy in controlling epidemic of cholera and watery diarrhoea. J. Indian Med. Assoc. 101 6 (2003) 379-386
19. Memon I.A., and Murtaza G. Drug sensitivity pattern of cholera in children. J. Pak. Med. Assoc. 52 8 (2002) 347-348
20. Taneja N., Kaur J., Sharma K., Singh M., Kalra J.K., Sharma N.M., et al. A recent outbreak of cholera due to Vibrio cholerae 01 Ogawa in and around Chandigarh, North India. Indian J. Med. Res. 117 (2003) 243-246
21. Champetier de Ribes G, Rakotonjanabelo LA, Migliani R, Pfister P, Rakotondramarina LD, Ranjalahy J, et al. Bilan d'un an d'évolution de l'épidémie de choléra à Madagascar de mars 1999 à mars 2000. Cahiers d'études et de recherches francophones-Santé. 2000 ; 10 (No 4) : 277-86.
22. Djadou K., Atakouma D., Agbobli-Apetsiani E., and Assimadi K. Épidémie de choléra à Dapaong (Togo) de juillet à octobre 1998 : cas de l'hôpital d'enfants. Med. Afr. Noire 48 5 (2001) 187-190
23. Bonnetblanc J.M. Doxycycline. Ann. Dermatol. Venereol. 129 6-7 (2002) 874-882
24. Isaac-Marquez A.P., Lezama-Davila C.M., Eslava-Campos C., Navarro-Ocana A., and Cravioto-Quintana A. Serotypes of Vibrio cholerae non-01 isolated from water supplies for human consumption in Campeche, Mexico and their antibiotic susceptibility pattern. Mem. Inst. Oswaldo Cruz 93 1 (1998) 17-22
25. Giono-Cerezo S., Rodriguez Angeles M.G., Gutierrez-Cogco L., and Valdespino-Gomez J. L. Phenotypic and genotypic characterization of Vibrio cholerae 01. Rev. Latinoam. Microbiol. 36 4 (1994) 243-251
26. Siddique A.K., Salam A., Islam M.S., Akram K., Majumdar R.N., Zaman K., et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaïre. Lancet 345 8946 (1995) 359-361
27. Iwanaga M., Toma C., Miyazato T., Insisiengmay S., Nakasone N., and Ehara M. Antibiotic resistance conferred by a Class 1 integron and SXT Constin in Vibrio cholerae 01 strains isolated in Laos. Antimicrob. Agents Chemother. 48 7 (2004) 2364-2369
28. Dalsgaard A., Forslund A., Sandvang D., Arntzen L., and Keddy K. Vibrio cholerae 01 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons. J. Antimicrob. Chemother. 48 (2001) 827-838
29. Khan W.A., Bennish M., Seas C., Khan E.H., Ronan A., Dhar U., et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 348 9023 (1996) 296-300
30. Giono-Cerezo S., Zarate A., Gutierrez L., and Valdespino J.L. Antibiotic resistance pattern of 24, 526 strains of Vibrio cholerae 01 isolated in Mexico from 1991 to 1993. Rev. Latinoam. Microbiol. 36 4 (1994) 257-262
31. Petroni A., Corso A., Melano R., Cacace M.L., Bru A.M., Rossi A., et al. Plasmidic extended-spectrum betalactamases in Vibrio cholerae 01 El Tor Isolates in Argentina. Antimicrob. Agents Chemother. 46 5 (2002) 1462-1468
32. Phantouamath B., Sithivong N., Sisavath L., Munnalath K., Khampheng C., Insisiengmay S., et al. Transition of drug susceptibilities of Vibrio cholerae 01 in Lao people's Democratic Republic. Southeast Asian J. Trop. Med. Public Health 32 1 (2001) 95-99
33. Waldor M.K., Tschäpe H., and Mekalanos J.J. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae 0139. J. Bacteriol. 178 (1996) 4157-4165
34. Dalsgaard A., Forslund A., Serichantalergs O., and Sandvang D. Distribution and content of Class 1 integrons in different Vibrio cholerae O-serotype strains isolated in Thailand. Antimicrob. Agents Chemother. 44 5 (2000) 1315-1321